EIQ.AX is trading 33.9% up at A$1.66 after announcing a strategic investment and U.S. distribution partnership with Pro Medicus.

  • The binding agreement includes up to A$20 million in secured convertible notes and debt funding to support growth initiatives.
  • Pro Medicus will lead a U.S. distribution arrangement for Echo IQ’s AI cardiac tools, providing a significant path to market.
  • Investors are treating the deal as a major commercialisation milestone and a key validation of the company's technology.